Breast Cancer

Galen Shearn-Nance, BS, and Johnie Rose, MD, PhD, of Case Western Reserve University, acknowledge key limitations of their study and prioritize areas for further research.

No significant differences in treatment or outcomes were found between most Medicare Advantage (MA) and fee-for-service (FFS) beneficiaries with breast cancer, but Black patients with FFS Medicare were less likely to receive standard treatment.

As Medicare Advantage (MA) enrollment grows, Johnie Rose, MD, PhD, Case Western Reserve University School of Medicine, underscores the importance of ongoing research into outcomes for MA beneficiaries vs fee-for-service (FFS) Medicare beneficiaries.

This study examined postdiagnosis breast cancer treatment outcomes for Medicare Advantage vs fee-for-service (FFS) Medicare in Ohio and found no significant differences overall but disparities for Black patients with FFS Medicare.

Interval breast cancer rates have remained consistent over 30 years despite age-based screening, highlighting the need for risk-based screening strategies that account for factors like breast density, hormone replacement therapy, and family cancer history to improve early detection.

Jade E. Jones, MD, of Emory Winship Cancer Institute, shares how considering patients' travel needs, social services, and insurance concerns can help improve access to care.

Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, provides new insights on the role of TROP2-directed antibody drug conjugates (ADCs) for patients with breast cancer.

For this retrospective study, the authors examined data on more than 3 million screening mammographies for more than 1 million female patients; of the screenings, 23.6% had abnormal results and only 6.7% were recommended for biopsy.

Racial and ethnic disparities were identified in immunotherapy receipt for Black patients with metastatic triple-negative breast cancer.

Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, discusses findings from the TROPION-Breast01 study on datapotamab deruxtecan for patients with HR-positive/HER2-negative breast cancer.

A follow-up of the ShortHER trial suggests tumor-infiltrating lymphocytes (TILs) can help identify patients who may benefit from shorter trastuzumab and chemotherapy regimens.

Significant increases in breast cancer incidence were found among Hispanic, American Indian or Alaska Native, and Asian or Pacific Islander women.

Breast cancer screening rates shifted after the 2009 US Preventive Services Task Force (USPSTF) guidelines, with disparities emerging across race, income, and lifestyle factors.

Sarah Anderson, oncology strategy lead director, Novotech, discusses the significance of triple-negative breast cancer research in the Asia-Pacific region, and the importance of clinical trial diversity in this region.

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted therapy.

Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, according to a global phase 3 trial.

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

Sarah Anderson, oncology strategy lead director, Novotech, discusses the growing prominence of triple-negative breast cancer clinical trials in the Asia-Pacific region, and the significant investments being made with novel biomarkers.

The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.

Dawn Klemow, MD, assistant clinical professor, University of Texas Southwestern Medical Center, previews some of the most recent advances in breast cancer treatment.

The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially lower health care costs.

A new analysis of the Breast Cancer Index (BCI) may help identify women with HR-positive breast cancer who could potentially benefit from shorter or less-intensive treatment.

Trial confirms elinzanetant's efficacy and safety in addressing vasomotor symptoms caused by adjuvant endocrine therapy in patients with hormone receptor–positive breast cancer.

Self-efficacy–based sexual counseling may improve sexual function among breast cancer survivors, study finds.

Alcohol was first identified as a carcinogen almost 40 years ago, by the World Health Organization's International Agency for Research on Cancer.